The introduction of nicotinamide for a nicotine alternative in e-cigarette and smokeless goods represents a substantial regulatory challenge to the FDA. Nicotinamide does not have nicotinic receptor agonist activity and is understood to act as a sedative at superior dosages6. The promises produced by Nicotine River, ECBlend, together with other sel